state Massachusets covid-19 testing pandemic vaccine state Massachusets

Rapid Micro Biosystems raises $120m: improving contamination testing in pharma

Reading now: 853
www.pharmaceutical-technology.com

Massachusetts-based Rapid Micro Biosystems has closed a $120m financing round, led by the new investors Ally Bridge Group and Endeavour Vision.

Existing investors, including  Bain Capital Life Sciences, Longitude Capital, Xeraya Capital and Asahi Kasei Medical, also participated in the funding round.

Rapid Micro Biosystems is a crucial player behind the scenes of the pharmaceutical industry; the company provides automated, high-throughput microbial detection technology for manufacturing through its Growth Direct platform.

The company plans to use this $120m of funding to accelerate the global expansion of this technology to meet growing demand, particularly in the context of Covid-19 and its disruption of pharma manufacturing. Importance

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA